Parkinson's-Focused Biotie's US IPO Hits Increased Target
Venture capital-backed Parkinson's disease treatment developer Biotie Therapies Corp. hit sweetened terms in its initial public offering Thursday, as the Finnish company became the latest European biotech to list in the...To view the full article, register now.
Already a subscriber? Click here to view full article